ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Health Technology

Healios KK

Business Summary

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. It develops therapies for ischemic stroke, acute respiratory distress syndrome, liver disease, and age-regulated macular degeneration. The company was founded by Tadahisa Kagimoto on February 24, 2011 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2019 JPYUSD
Revenue00
Gross Profit-69M-0.63M
Operating income-4,271M-39.17M
Income before tax-4,403M-40.39M
Net income-4,410M-40.45M
EBITDA-4,202M-38.54M
Diluted EPS-87.96-0.80
Dividends Per Share00
Total Assets21,101M194.16M
Total liabilities12,124M111.56M
Total equity8,976M82.59M
Operating cash flow-4,970M-45.59M
Currency in JPYCurrency in USD

Historical Data

 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 98.16M 77.64M 27.66M 0 0
Gross Profit -74.69M -100.81M -75.96M -78M -69M
Operating income -1,060.41M -3,507.46M -2,348.20M -5,063M -4,271M
Income before tax -958.12M -3,426.74M -1,771.55M -5,091M -4,403M
Net income -958.10M -3,433.55M -1,776.65M -5,097M -4,410M
EBITDA -896.94M -3,338.15M -2,247.89M -4,985M -4,202M
Diluted EPS -25.60 -84.33 -39.73 -103.51 -87.96
Dividends Per Share 0 0 0 0 0
Total Assets 10,487.61M 9,174.98M 19,696.42M 14,980M 21,101M
Total liabilities 1,110.25M 3,180.55M 3,532.74M 4,196M 12,124M
Total equity 9,377.36M 5,994.42M 16,163.67M 10,782M 8,976M
Operating cash flow -167.17M -3,782.67M -1,762.18M -5,148M -4,970M
 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 0.81M 0.71M 0.24M 0 0
Gross Profit -0.61M -0.92M -0.67M -0.70M -0.63M
Operating income -8.75M -32.27M -20.94M -45.84M -39.17M
Income before tax -7.91M -31.53M -15.79M -46.09M -40.39M
Net income -7.91M -31.59M -15.84M -46.15M -40.45M
EBITDA -7.40M -30.72M -20.04M -45.13M -38.54M
Diluted EPS -0.21 -0.77 -0.35 -0.93 -0.80
Dividends Per Share 0 0 0 0 0
Total Assets 87.18M 78.66M 174.84M 136.53M 194.16M
Total liabilities 9.22M 27.26M 31.36M 38.24M 111.56M
Total equity 77.95M 51.39M 143.48M 98.27M 82.59M
Operating cash flow -1.38M -34.81M -15.71M -46.61M -45.59M

Valuation Measures

Dec 2019
PER--
ROA-24.44%
ROE-44.64%
Operating margin--
Profit margin--

Key executives

  • President, Chief Executive Officer & Director: Tadahisa Kagimoto
  • Chief Financial Officer & Director: Richard Patrick Kincaid
  • Chief Medical Officer & Executive Vice President: Masanori Sawada
  • Executive Officer, Head-Research & Production Area: Kouichi Tamura
  • Executive Officer & Head-Development Area: Michihisa Nishiyama

Shareholders

  • KAGIMOTO TADAHISA (55.1%)
  • JPMorgan Asset Management (Japan) Ltd. (3.9%)
  • Baillie Gifford & Co. (3.8%)
  • Asset Management One Co., Ltd. (3.8%)
  • Nikon Corp. (2.9%)
  • Sumitomo Dainippon Pharma Co., Ltd. (2.9%)
  • Nomura Asset Management Co., Ltd. (2.2%)
  • Matthews International Capital Management LLC (2.2%)
  • FUJIOKA YOSHIHISA (1.3%)
  • TAKEDA HIDEKI /HEALIOS/ (1.0%)

Contact Details

Related Companies

  • Healios N.A., Inc.
  • Sighregen Co., Ltd.

Competitors

  • Roche Holding AG
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Santen Pharmaceutical Co., Ltd.
  • Pluristem Therapeutics Inc.
Last Updated on 23 Oct, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more